Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2026-03-27 @ 7:27 PM
Study NCT ID:
NCT00442650
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
25030
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None